TIDMAGL

RNS Number : 5364F

Angle PLC

12 November 2015

 
 For immediate release    12 November 2015

ANGLE plc ("the Company")

ISSUE OF SHARE OPTIONS

ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, announces that in relation to the Annual Bonus Plan set out in the Company's 2015 Annual Report and Accounts, the following share options over the Company's ordinary shares of GBP0.10 ("bonus options") were granted today to the following Directors of the Company:

 
                   Number of Ordinary Shares over 
 Director           which bonus options have been granted 
 Andrew Newland    73,826 
 Ian Griffiths     46,980

The bonus options granted are exercisable at par value and have a 10 year life. There are no performance conditions.

For further information:

 
 ANGLE plc                                01483 685830 
 Andrew Newland, Chief Executive 
  Ian Griffiths, Finance Director 
 Cenkos Securities 
  Stephen Keys, Dr Christopher Golden 
  (Nominated adviser) 
  Russell Kerr, Olly Baxendale (Sales)    020 7397 8900 
 FTI Consulting 
  Simon Conway, Mo Noonan, Stephanie 
   Cuthbert                                020 3727 1000 
  Kimberly Ha (US)                          001 212 850 5612

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

   About ANGLE plc     www.angleplc.com

ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the Parsortix system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in the United States, China and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The Parsortix system is established with strong positive evaluations from leading cancer research centres and is working with these cancer centres to demonstrate key applications. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States.

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi $billion clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

Now that the Parsortix system has been developed, ANGLE is focused on its commercialisation in the market.

ANGLE is strongly focused on establishing the use of the Parsortix system in clinical practice. To achieve this, ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. ANGLE believes this is the optimal approach for unlocking the multi-billion dollar worldwide market available to the Company and its potential strategic partners. Details are available here http://www.angleplc.com/the-company/collaborators/

As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.

ANGLE began trading on the AIM market of the London Stock Exchange in March 2004 under the ticker symbol AGL. For further information please visit: www.angleplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSUUASRVAAAAAA

(END) Dow Jones Newswires

November 12, 2015 09:17 ET (14:17 GMT)

Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Angle Charts.
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Angle Charts.